Prazer Therapeutics Raises $20M in Series B to Accelerate PAQ Therapeutics’ Revolutionary ATTEC Platform

We are thrilled to announce that Prazer Therapeutics has successfully raised $20 million in its latest funding round, marking a pivotal moment for the company and the future of biotechnology.

With a groundbreaking approach to restoring health and curing disease through the fascinating process of autophagy, Prazer Therapeutics, operating under the visionary framework developed by PAQ Therapeutics, is positioned to redefine drug discovery and development.

At the core of this transformative initiative is the innovative ATTEC (autophagosome-tethering compound) technology, a novel platform that leverages the body’s intrinsic cellular degradation pathway to target and eliminate an array of harmful substrates, including proteins, aggregates, lipids, organelles, and pathogens.

This unique strategy not only holds the promise of addressing complex diseases from a cellular perspective but also paves the way for new therapeutic avenues that could significantly improve patient outcomes.

The capital infusion of $20 million will be strategically deployed to advance critical research and development efforts, accelerate preclinical studies, and fine-tune the ATTEC technology to optimize its efficacy and safety profiles.

This funding milestone underscores the confidence of our investors in the potential of our science-driven approach and reaffirms our commitment to pushing the boundaries of traditional therapeutics.

As we embark on the next phase of our journey, we are excited by the prospect of bringing forward a new class of small molecule degraders that could transform the treatment landscape for diseases that were once considered intractable.

Stay tuned for more updates as we continue to work towards unlocking the full potential of autophagy to revolutionize healthcare.